trending Market Intelligence /marketintelligence/en/news-insights/trending/71TFJet5x3ll5As3yGqa7w2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Kyowa Hakko sets up new company to advance generic medicine

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity


Kyowa Hakko sets up new company to advance generic medicine

Japan-based Kyowa Hakko Kirin Co. Ltd. established Kyowa Kirin Frontier Co. Ltd. with ¥100 million in capital.

The new company will work on getting manufacturing and marketing approval for an authorized generic of NESP, Kyowa Hakko Kirin's key product to help boost red blood cell production in kidney disease patients with anemia.

Kyowa Kirin Frontier will be headed by Wataru Murata as CEO and executive director of the board.

As of Jan. 31, US$1 was equivalent to ¥112.39.